AXSM Earnings Date: Nov 2, 2026 (Estimated) — Axsome Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is AXSM's next earnings date?
Axsome Therapeutics, Inc. (AXSM) is expected to report Q3 2026 earnings on Monday, November 2, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.63 on revenue of $249.2M.
How did AXSM do in its last earnings report?
In its most recent report on Aug 10, 2026 (Q2 2026), Axsome Therapeutics, Inc. posted EPS of -$0.99 versus the -$0.89 estimate, a miss of 13.8%. Revenue was $218.4M against a $221.1M estimate. The stock's 1-day post-earnings move was +3.8%.
How much does AXSM stock move after earnings?
AXSM beat EPS estimates in 6 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 4.3% (up or down) in the day after earnings.
About Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-10 | Q2 2026 | -0.89 | -0.99 | -13.79% | $218.4M | ❌ Miss | +3.83% | +0.44% | -2.31% |
| 2026-05-04 | Q1 2026 | -0.83 | -1.26 | -51.81% | $191.2M | ❌ Miss | +8.31% | +5.25% | +7.57% |
| 2026-02-23 | Q4 2025 | -0.72 | -0.56 | +22.22% | $196.0M | ✅ Beat | -4.88% | -10.79% | -14.63% |
| 2025-11-03 | Q3 2025 | -0.87 | -0.68 | +21.84% | $171.0M | ✅ Beat | +0.56% | +2.34% | +5.26% |
| 2025-08-04 | Q2 2025 | -1.05 | -0.47 | +55.66% | $150.0M | ✅ Beat | +3.42% | +1.73% | +19.85% |
| 2025-02-18 | Q4 2024 | -0.99 | -0.80 | +19.19% | $118.8M | ✅ Beat | -2.33% | -0.33% | -4.87% |
| 2024-11-12 | Q3 2024 | -1.41 | -0.49 | +65.25% | $104.8M | ✅ Beat | +9.35% | +1.62% | +7.43% |
| 2024-05-06 | Q1 2024 | -1.21 | -1.00 | +17.36% | $75.0M | ✅ Beat | +1.52% | -3.07% | -3.42% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $218.4M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Product | 99.1% | $216.4M | +45.2% | $203.8M | $120.4M | $149.0M | $169.8M |
| Royalty | 0.7% | $1.5M | +36.1% | — | $1.1M | $1.1M | $2.1M |
| Milestone Revenue | 0.3% | $546K | — | — | — | — | — |
By region
Q2 FY26 · $217.4M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 99.1% | $215.4M | +47.1% | $116.6M | $119.4M | $146.4M | $169.2M |
| Non-US | 0.9% | $2.0M | -19.6% | $1.0M | $1.1M | $2.5M | $1.2M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.